Standard BioTools ( ) - 株価, ニュースと分析Nasdaq:SLGC

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

SLGC 株式概要

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States.

SLGC ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	1/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

報酬

収益は年間16.43%増加すると予測されています

リスク分析

過去3か月間の株価の変動

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Standard BioTools Inc. 競合他社

Cryoport

NasdaqCM:CYRX

US$393.8m

Pacific Biosciences of California

NasdaqGS:PACB

US$474.2m

ChromaDex

NasdaqCM:CDXC

US$287.7m

Quanterix

NasdaqGM:QTRX

US$498.2m

価格と性能

の歴代最高値、変動、値下がりまとめStandard BioTools
過去の株価
現在の株価	US$2.10
52週高値	US$3.79
52週安値	US$1.73
ベータ	1.64
11ヶ月の変化	-13.93%
3ヶ月変化	14.13%
1年変化	-28.08%
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	n/a

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

株主還元

	SLGC	US Life Sciences	US 市場
7D	-14.3%	0.3%	0.9%
1Y	-28.1%	12.6%	32.4%

業界別リターン: SLGC過去 1 年間で3.5 % の収益を上げたUS Life Sciences業界を下回りました。

リターン対市場: SLGCは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is SLGC's price volatile compared to industry and market?
SLGC volatility
SLGC Average Weekly Movement	11.4%
Life Sciences Industry Average Movement	9.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

安定した株価: SLGCの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: SLGCの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1999	451	Adam Taich	www.somalogic.com

Standard BioTools Inc. 基礎のまとめ

Standard BioTools の収益と売上を時価総額と比較するとどうか。
SLGC 基礎統計学
時価総額	US$396.23m
収益（TTM）	-US$130.38m
売上高(TTM)	US$81.72m

4.8x

P/Sレシオ

-3.0x

PER（株価収益率

SLGC は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
SLGC 損益計算書（TTM）
収益	US$81.72m
売上原価	US$97.89m
売上総利益	-US$16.16m
その他の費用	US$114.22m
収益	-US$130.38m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.69
グロス・マージン	-19.78%
純利益率	-159.54%
有利子負債／自己資本比率	0%

SLGC の長期的なパフォーマンスは？

過去の実績と比較を見る

SLGC 株式概要

報酬

リスク分析

Standard BioTools Inc. 競合他社

NasdaqCM:CYRX

US$393.8m

NasdaqGS:PACB

US$474.2m

NasdaqCM:CDXC

US$287.7m

NasdaqGM:QTRX

US$498.2m

価格と性能

最新ニュース

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 21% to US$3.93

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Less than half of directors are independent

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$6.50

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Consensus forecasts updated

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

SomaLogic appoints former Foundation Medicine chief as executive chair

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Consensus forecasts updated

SomaLogic Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$7.75

Price target decreased to US$11.50

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Price target decreased to US$14.50

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Independent Director exercised options to buy US$275k worth of stock.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Now 24% undervalued after recent price drop

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022